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LETTERS TQ THE EDITOR, 
,Low Density Lipoprotein Oxidation and 
Variant Angina: Role of Methodologic 
Procedures in Assessment of Oxidizability of 
Low Density Lipoprotein 
I read with great interest the results of the study hy Miwa et al. (I) 
dealing with the role of copper-induced peroxidized low density 
lipoprotein (LDL) in patients with variant angina. The authors con- 
clude from their observations that LDL in these patients was highly 
susceptible to peroxidative modification in association with less vita- 
min E content than that in patients with inactive coronary spasm. This 
conclusion may be questionable, although the results are provocative 
and may justify further studies. Oxidized LDI, isolated from athero- 
sclerotic arteries, is similar to LDL oxidized in vitro with copper (range 
5 to 20 pM) (2). Many groups use copper ions to peroxidixe LDL in 
vitro (2) and probably study reactions involving preformed hydroper- 
oxides. In fact, copper ions will not cause peroxidation in completely 
peroxide-free LDL (3). This phenomenon highlights the risk of 
misleading results in interpreting the pathophysiologic significance of 
copper-peroxidized LDL Computer simulation revealed that the 
average concentration of Cu’* was 10-l” mol/liter, with a conservative 
upper limit of IO-” mol/liter, whereas the mean free iron (Fe”) was 
lo-” mol/bter (4). Thus, micromolar concentrations of copper are 
millions-fold higher than physiologic concentrations. In addition. one 
should not infer from in vitro oxidation by free copper (Cu’+) that 
such a process occurs in vivo because Cu2+ is unlikely to occur in vivo. 
Copper is a member of the first transition series of elements, and in 
aqueous solution, ions of these eiemcnts form well defined aqua ions. 
Because these water molecules can be displaced completely by other 
ligands only with diBiculty, one can infer that Cu’+ never occurs on 
aqueous media. Several studies (2,5.6) used different methods to 
oxidize LDL (cells, polymorphonuclear leukocytes, xanthine oxidase. 
ceruloplasmin). 
Another important issue is the length of the LDL isolation pro 
cedure. Miwa et al. (1) isolated LDL with sequential ultracentrifuga- 
tions, and LDL was then extensively dialyzed (40 to 48 h). Both the 
long-term ultracentrifugation procedure (2 days) and dialysis and the 
long-term storage of LDL at 4°C before use may induce a lost of 
endogenous antioxidants (7) and contribute to generating prooxidant 
conditions. We prefer to use a single-step. rrpid ultraccntrifugation 
with a vertical rotor (1 h) coupled with the Sephacryl S-3&l column 
(2 min) to desalt LDL samples (5,6). 
A major determinant of LDL peroxidation is its fatty acid compo- 
sition (2). Iinoleic and arachidonic acids enhance oxidixability with 
major susceptibility of double bonds to peroxidation. In contrast, the 
increased content of okic acid, which contains a single doubk bond. 
enhances the resistance to oxidation. Therefore, the fatty acid compo 
sition must be determined in studks aimed at identifying differences in 
LDL peroxidation among diflerent classes of patients. 
The makndiahkhyde (MDA) content of LDL was assayed by the 
thiobarbiturie acid method (1). Artiiactual pemxidation during. the 
pmeedure could be prevented by adding the chain breaker butylated 
bydroxytduew (10 mmoiJiter). the iron chelator defemxamine (100 
rmollliter) and &and (0.16%) to the sampks before the TBA 
teagents are added (56). Malondialdehyde is a widely used marker of 
pemida* tnnwever. as the authom xhnowk&, the propagation 
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phase of lipid peroxidation is a nrorc adequate crr:imation of LDL 
susceptibility to peroXidation. The following indexes should be deter. 
mined (6): 1) the initial 234.nm absorbance: 2) the lag time. detined as 
the interval between the intcrcepl of the linear least square slope ot the 
curve with the initial absorbance axis; 3) the maximal rate of oxidation. 
calculated from the slope of the absorbance curve during the propa- 
gation phase: 4) the maximal amount of dienes produced. Finally. the 
authors did not provide a pathophysiologic explanation of why patients 
with variant angina had low levels of vitamin E (I). 
In conclusion. although the primary finding of the study (1) is very 
interesting. further studies are necessary before dcfinitivc conclusions 
addressing the issues raised by Miwa et al. can he made. 
Referencer 
We thank Napoli for his interest in our report (I j. We agree that cupric 
ion-induced oxidation of low density lipoprotein (LDL) is unlikely to 
occur in viva. and the concentrations of cupric ion used in our in vitro 
experiments were much higher than those in physiologic rxxrce.ntra- 
tions. Our study demonstrated that plasma LDL from patients uith 
active variant angina was highly susceptible to cupric ion-induced 
peroxidativ:: modification in association with a lower vitamin Econtent 
than LDL from patients without coronary spasm. Although the precise 
mechanisms by which oxidative modihcation of LDL is triggered in 
vivo are yet to bc ehrcidated. the susceptibility to osidatiott demon- 
strated in our study may be extrapolated or generalized to other 
oxidation p’oceges suchasfrceradkal+ducedosidationofLDL 
We also appreciate the comments made by Napoli tith regard to 
our methods including the isolation procedure and the estimation d 
the oxidative su~cepc~GIity to cupric ion used in our study and wouhi 
IiLL to ~iarify wme points meotiomzd by him. Actualty. we used a 
squentid rapid uIttaantrifugation step with a serniverticd rotor (3 b 
~2).IndecdtbeamccntrationdvitamiaEinU)Lrnryhave~ 
redueedafierdia@&audtheLDLparti&usediuourstudymayuut 
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he truly representative of freshly isolated lipoproteins. However, the 
stock titrz and the dialysis conditions were not, different among the 
groups. Recently. we reported ‘that vitamin E was also deficient in 
plasma from patients with variant angina (2). The vitamin E level was 
found to be significantly correlated between isolated LDL fraction that 
had been dialyzed and plasma (2). Fatty acid composition may also 
affect LDL oxidizability and remains to be determined. as suggested by 
Napoli. We agree that the propagation phase of lipid peroxidation is a 
more adequate estimation of LDL susceptibility to peroxidation. as 
suggested by Napoli, although the production of thiobarbituric acid- 
reactive substances after 24-h incubation with 0.5 pmohliter Cu” was 
used as a convenient index for the resistance or oxidizability in a 
previous study (3) and in the present study as well. 
Our study demonstrated an association between vitamin E defi- 
ciency and coronary spasm. However, the exact causal relation be- 
tween them is unkrown. The low levels of vitamin E may be the result 
of exhaustion of this antioxidant by increased lipid oxidatior stress, 
such as free radical production induced by frequently repeated alter- 
ation between severe transient regional myocardial &hernia and 
reperfusion. In contrast, it is also possible that the oxidiaability of LDL 
could be directly related to the pathogenesis of coronap. spasm. 
Oxygen-derived free radicals within the vasculature may initiate a 
vicious cycle by oxidizing LDL. which in turn may inhibit endnthelium- 
dependent vacrdilation and may also potenti:te agonist-induced vaso- 
constriction, leading to transient regional myocardial ischemia. Vita- 
min E deficiency may be involved in this vicious cyLle in the 
pathogenesis of coronary artery spasm. 
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Non-Q Wave Infarction After 
Thrombolytic Therapy 
1 am concerned by the potential for misinterpretation of data pre- 
sented by Langer et al. (1) with respect o non-Q wave infarction after 
thrombolytic therapy in the Late Assessment of Thrombolytic Eflicacy 
(LATE) study. They interpret their results to show that “patients with 
a non-Q wave infarction who have received thrombolytic therapy may 
have a better prognosis than those given placebo.” Although t!x &tdy 
is provocative in many .regar&. as presented it rakes substantial 
~concem for misin!erpretation and bias. 
Non-Q wave myocardial infarction was determined at hospital 
diiharge. Hence, it was not a baseline variable (present at the time of 
randomiaation), but rather an “outcome variable.” As such, it was 
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subject to bias, for example. a treatment effect that most likely led to 
noncomparable groups (i.e.. the comparability expected at randomiza- 
tion was lost). A greater percentage of patients with ST segment 
elevation myocardial infarction (MI) treated at baseline may have 
developed non-Q wave infarction, yielding an overaii group with a 
better prognosis. A second and somewhat related problem is defini- 
tional. On the presenting elt=ztrocardiogram, ST elevation versus 
non-ST elevation can be determined. but on!! at discharge can a clear 
interpretation of non-Q wave r’ersus Q wave Ml be made. The two 
contrasts are not equivalent. ST elevation MI may evolve to non-Q 
wave MI, and. less commonly, patients initially presenting without ST 
elevation may evolve through additional changes, resulting in Q wave 
MI. Finally. as the authors point out, their results arc post hoc 
analyses. They propose two new treatment-related hypotheses: First, 
patients with ST elevation presenting “late” benefit from thrombolytic 
therapy only if treated within 3 h of symptom onset, whereas those 
presenting late but treated late show an adverse trend. This hypothesis 
suggests that two fundamentally different groups of patients were 
recruited into rhe LATE study and that these two groups need to be 
better defined. One group of patients with prolonged pain (~6 h) and 
marked ST depression (>2 mm) may benefit from thrombolysis, 
although previous stutdics have shown that these patients, presenting 
early. will not benefit. In view of the much larger data base including 
studies showing an absence of benefit with ST depression using 
primary hypothesis testing (Thrzb~lysis iu Myocardial Lfarction- 
III), the contradictory findings of Langer et al. clearly will require 
prospective verification. 
Given the potential for bias and for confusion of these data and the 
unusual heterogeneity of patient groups recruited, a cautionary note 
should be raised. It certainly would be unwise to change our current 
thrombolytic therapy algorithm for acute MI on the basis of the results 
presented by Langcr et al. 
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We appreciate the opportunity to amplify further some issues arising 
from our recent report and raised by Anderson’s thoughtful letter. 
Rccause non-Q wave myocardial infarction is a diagnosis made 
retrospectively and not on hospital admission, Anderson raises con- 
cerns that it is subject to bias. Importantly. however. patients in the 
Late Assessment of Myocardial Efficacy (LATE) study (I) presenting 
with ST segment elevation developed non-Q wave myocardial infarc- 
tion with equal frequency in both tissue-type plasminogen- and 
placebo-treated groups, and the study remained randomized and 
placebo controlled. Hence, bias is unlikely. 
To be sure, there was heterogeny among patients enrolled in the 
LATE study, as hasbeen’the case with other large thrombolytie triak 
with a wide temporal window (International Study of Infarct Survival 
(ISIS] II). Patients in the LATE study with benefit from thrombolytie 
theram who had ST segment elevation were tkosc treated within 3 h of 
prcscntation to bospii not within 3 h ofsymptom onset; this point 
was identified as an important outcome variable in the initial IAfE 
